Cancer Research - McMaster Experts

publication venue for

Genome-wide study identifies novel genes associated with bone toxicities among children with acute lymphoblastic leukemia 2024
Phase I clinical study of Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) 2024
FLCN variants and their role in parathyroid cancer and atypical parathyroid tumors 2024
HBW-012-D and HBW-012-E are novel, potent, selective, safe, and bioavailable KRAS G12D inhibitors with superior anti-tumor efficacy in mice 2024
Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis 2023
Abstract 5279: Molecular analysis of AMBRA1 as a candidate tumor suppressor in sporadic parathyroid adenomas 2023
Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing 2023
The effects of tumor cell-secreted factors on endothelial cell junction phenotype 2023
Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC 2022
Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma 2022
HLA-G, SPAG9 and STAT3 signalling: An alliance that promotes early-stage brain metastases 2022
Interrogating the pre-metastastic gene signature to block brain metastases 2022
KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC 2022
Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer 2022
Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER) 2022
Abstract 2818: In vivo imaging of mitochondrial bioenergetics in lung cancer 2021
Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. 2021
In vivo imaging of mitochondrial bioenergetics in lung cancer. 2021
Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415. 2021
Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models. 2021
A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer 2021
A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01) 2021
Evaluation of sleep problems and their association with febrile neutropenia, leucopenia and infections in women receiving adjuvant chemotherapy for breast cancer in the Canadian Cancer Trials Group MA.21 trial 2021
Mastectomy versus breast conserving surgery for the management of locally advanced breast cancer 2021
Abstract 1621: Contactin 1 (CNTN1) promotes prostate cancer tumorigenesis in transgenic models 2020
Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade 2020
Abstract P1-15-09: What are the outcomes of importance for patient education in breast cancer? 2020
Abstract P2-18-01: Single modality adjuvant therapy with radiation (RT) alone or endocrine therapy (ET) alone in women ≥65 years with early stage, hormone receptor positive breast cancer treated with breast-conserving surgery: A population-based analysis 2020
Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer 2020
Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study 2020
Abstract P5-12-06: Non-adherence to endocrine therapy is associated with a significant increased risk of local recurrence in women ≥65 years with stage T1N0 breast cancer treated with adjuvant endocrine therapy alone after breast-conserving surgery 2020
Abstract P6-13-02: Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: A cost-minimization study 2020
Abstract P6-16-01: Refined local recurrence risk estimates based on a multigene expression assay combined with clinicopathological features significantly impacts radiotherapy recommendation in patients with low/intermediate risk DCIS treated with breast-conserving surgery 2020
Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies 2019
Abstract 3682: Therapeutic targeting of stem cell self-renewal in childhood medulloblastoma: Strategies for blocking recurrence 2019
Abstract 3682: Therapeutic targeting of stem cell self-renewal in childhood medulloblastoma: Strategies for blocking recurrence 2019
Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence 2019
Abstract 768: miR-378a-5p acts as a positive regulator of melanoma progression 2019
Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO) 2019
Abstract ES4-2: Treatment morbidity and quality of life considerations 2019
Abstract GS4-02: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials 2019
Abstract GS4-03: RAPID: A randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT) 2019
Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial 2019
Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results 2019
Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693) 2019
Abstract 1140: Genes preserving stem cell state in group 3 medulloblastoma brain tumor initiating cells contribute to therapy evasion and relapse 2018
Abstract 148: Canonical Wnt activation as a therapeutic strategy in pediatric medulloblastoma 2018
Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies 2018
Abstract 1911: Uncovering novel targets of recurrent glioblastoma using transcriptomic profiling in a patient-derived xenograft model 2018
Abstract 2556: Expanded ovarian cancer patient NK cells represent a novel, cytotoxic phenotype and reduce autologous tumor in a patient-derived xenograft ovarian cancer model 2018
Abstract 3162: Endothelin-1 receptor/beta-arrestin-1 pathway promotes invadopodia and metastatic process by integration with hMENA in human serous ovarian cancer 2018
Abstract 350: Che-1/aatf-induced transcriptionally active chromatin promotes cell growth in multiple myeloma 2018
Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resistors of conventional chemoradiotherapy 2018
Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases 2018
Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) 2018
Abstract P5-20-17: Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study 2018
Effects of radiotherapy on breast cancer outcomes among stage I, low-Recurrence risk, hormone-Sensitive breast cancer: Pooled analysis of individual data from phase III trials 2018
Kaiso regulates miRNA-31 and miRNA-200 expression in triple negative breast cancer (TNBC) cells 2018
Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC) 2018
Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study 2018
Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit 2018
Validation that a histone gene signature predicts anthracycline response in early breast cancer 2018
Abstract 1197: Endothelin-1 receptor/β-arrestin1 is an actionable node that regulates YAP/TAZ signaling and chemoresistance in high-grade ovarian cancer 2017
Abstract 1830: Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer 2017
Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma 2017
Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma 2017
Abstract 3844: Identification and validation of novel therapeutic targets driving clonal heterogeneity in treatment-refractory GBM 2017
Abstract 3870: Clonal evolution of medulloblastoma BTICs in response to therapy 2017
Abstract 4258: Influence of lifestyle factors on adipocyte size in human breast tissue 2017
Abstract 4983: T cells expressing chimeric PD1 receptors that contain a Dap10 costimulatory domain are a potential treatment for multiple types of cancer 2017
Abstract 5831: Activated Wnt signaling for the treatment of recurrent medulloblastoma 2017
Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC) 2017
Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment 2017
Tumor immune profiling identifies multiple unique therapeutic targets that improve vaccination plus oncolytic virotherapy against metastatic ovarian cancer 2017
Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer 2017
Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study 2017
Abstract P3-02-02: Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors? 2017
Abstract P3-02-06: Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or high risk lesion 2017
Abstract P3-03-13: Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxyten species/SUMOylation pathway and its effects on xCT expression and system xc- activity 2017
Abstract P4-19-02: Young women with early stage breast cancer and their supportive care needs: Results from a regional survey 2017
Abstract P4-22-19: Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US 2017
Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab 2017
Abstract S6-01: BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) 2017
Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells 2016
Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors 2016
Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma 2016
Abstract 2680: Development and application of a novel model of human lung-to-brain metastasis: identification of TWIST2 and SPOCK1 as unique regulators of brain metastases 2016
Abstract 3787: Thyroid hormone induced proliferation of breast cancer cell lines: A novel approach to hormone therapy 2016
Abstract 4918: Emerging prognostic biomarkers in colorectal cancer: HURP and ZEB1 2016
Abstract 521: c-MYC as a differentiating marker between angiosarcoma and atypical vascular lesion 2016
Abstract P3-07-16: Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be? 2016
Abstract P3-08-04: Improving sleep to reduce breast cancer risk in shift workers 2016
Abstract S5-08: Late side-effects of breast cancer radiotherapy: Second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials 2016
Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be? 2016
Abstract 1154: Serum and urine markers of metabolic dysfunction in colorectal cancer: A pilot study 2015
Abstract 4346: Prognostic gene signature for intermediate risk prostate cancer 2015
Abstract 4960: ERp46 (thioredoxin domain-containing protein 5, TXND5) promotes prostate cancer growth in vitro and in vivo 2015
Abstract 5289: The role of the immune system in lymph node positive ER+ breast cancer 2015
Copy number and loss of heterozygosity (LOH) analysis in 52 breast cancer FFPE samples using molecular Inversion probe array: detailed analysis of reproducibility and performance compared to NGS platforms 2015
Abstract P2-05-05: A four gene signature predicts anthracycline benefit: Evidence from the BR9601 and MA5 breast cancer trials 2015
Abstract P3-07-09: Trends and determinants of breast cancer survival among unscreened women: A population-based study 2015
Abstract P3-07-13: Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011 2015
Abstract P4-11-06: TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial 2015
Abstract P5-07-05: Regulation of system Xc- by signal transducer and activator of transcription 3 and 5 in human breast cancer cells 2015
Lifestyle interventions combined with acupuncture-like transcutaneous electrical nerve stimulation in managing vasomotor symptoms induced by breast cancer treatment: Results of a phase 2 randomized controlled trial 2015
Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011 2015
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial 2015
Young Women with Breast Cancer: Needs and Experiences 2015
Abstract 3233: Targeting system xc- in breast cancer cells: Development of novel therapeutics 2014
Abstract 3687: Analgesic effects of capsazepine on a mouse model of bone cancer pain 2014
Abstract 3845: Symptoms burden in subjects with cervical cancer and supportive care:A view from a developing country 2014
Abstract 506: H2O2 upregulates xCT in human breast cancer cells via NRF-2 2014
Abstract 5392: High-throughput screening of compounds for targeting system Xc(-) in human breast cancer cells 2014
Abstract P1-07-12: Kaiso is a novel regulator of epithelial-to-mesenchymal transition in triple negative breast cancer cells 2013
Abstract P5-01-01: Lymphoid tissue inducer cells: Identification of a novel immune cell within the breast tumour microenvironment and its role in promoting tumour cell invasion 2013
Abstract P6-06-03: Differing patterns of treatment effect in a trial assessing sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) 2013
Abstract P6-07-02: Pharmacoeconomic evaluation of denosumab for the treatment of bone metastases in patients with advanced breast cancer in Canada 2013
Abstract A62: Thymic aplasia and decreased immunologic function: Possible factors behind cancer development 2013
Abstract C57: Observation of experimental and clinic curative effect on Z-C medicine treating malignancy 2013
Abstract 1107: β2-integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. 2013
Abstract LB-166: Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study. 2013
Abstract P1-13-01: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis. 2012
Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. 2012
Abstract P2-10-29: Time dependent breast cancer metastasis prediction using novel biological imaging, clinico-pathological and genomic data combined with Bayesian modeling to reduce over-fitting and improve on inter-cohort reproducibility. 2012
Abstract P2-12-03: A pilot study evaluating the benefits and feasibility of an exercise program for breast cancer patients receiving adjuvant chemotherapy. 2012
Abstract P2-14-01: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007) 2012
Abstract P6-09-02: Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls. 2012
Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019) 2012
A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients 2012
Abstract 1302: Effect of intestinal-specific Kaiso overexpression on the APC MIN/+ mouse colon cancer model 2012
Abstract 1428: A CpG island methylator phenotype defines a clinically aggressive subgroup of posterior fossa ependymoma 2012
Abstract 3663: A gene signature for predicting outcome in patients with basal-like breast cancer 2012
Abstract 5157: Prolactin plays a role in regulating fatty acid synthesis and metabolism in the prostate cancer cell line PC-3 2012
Abstract LB-230: A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients 2012
Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients 2012
How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. 2011
Molecular Classification with 21 Gene Assay (Oncotype DX) Shows in 196,967 ER Positive Patients High Frequency of Low Recurrence Score [LRS] in Both Node Positive (Ni-) and Negative (N-) Breast Cancer (BrCa) Cohorts. Definition of Chemoresistance Based on LRS with Cost and Guideline Implications. 2011
OT1-02-13: Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy. 2011
P2-12-27: Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer. 2011
P2-15-05: Excision of the Primary Tumour in Patients with Metastatic Breast Cancer – Will E2108 Provide the Definitive Answer? 2011
P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity. 2011
P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. 2011
P5-15-03: Development of a Patient Decision Aid for Women 70 Years and Older with Stage I, Hormonally Sensitive, Breast Cancer Considering Adjuvant Treatment Post-Lumpectomy. 2011
Abstract 2491: Metformin sensitizes human lung cancer xenografts to ionizing radiation: Response of the AMPK pathway 2011
Abstract 4071: Sestrins modulate the expression of the metabolic stress sensor AMPK in breast cancer cells 2011
Abstract 409: The influence of chronic low grade systemic inflammation on the progression of epithelial ovarian cancer 2011
Abstract 548: Multistage nanoparticle delivery system for deep penetration into solid tumor 2011
Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth in vivo 2011
Abstract LB-101: Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain 2011
Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer 2011
Acquired resistance to vorinostat in acute myeloid leukemia 2011
Abstract P2-11-01: Molecular Profiling Identifies Differentially Expressed Genes between Normal Breast Tissue from BRCA Carriers and Women at Population Risk 2010
Abstract P4-03-02: Establishing a Relationship between Breast Cancer, Prolactin and Altered Fat Metabolism 2010
Abstract P6-09-09: Dual Estrogen Effects on Breast Cancer: Endogenous Estrogen Stimulates, Exogenous Estrogen Protects. Further Investigation of Estrogen Chemoprevention Is Warranted 2010
Abstract 1239: The transcription factor Kaiso negatively regulates the hypoxia inducible factor-1 alpha 2010
Abstract 2983: Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation 2010
Abstract 3010: The advent of miRNAs in the molecular taxonomy of breast cancer 2010
Abstract 3694: The mitochondrial FAD-linked glycerol-3-phosphate dehydrogenase as an inhibitory target for cancer therapeutics 2010
Abstract 5780: Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK) 2010
Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies 2010
Amplification of the Prolactin Receptor Gene in Mammary Lobular Neoplasia 2009
Microtubule Associated Protein Tau Expression as a Predictive and Prognostic Marker in a Trial Assessing Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT). 2009
Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. 2009
A targeted, high-throughput screening approach for inhibitors of reactive oxygen species in prostate cancer cells. 2009
Anti-tumor activity of sunitinib and radiation is enhanced by soy isoflavones in murine renal cell carcinoma 2009
Characterization of glutamate transporters in cancer cells: Implications on normal bone formation. 2009
Effect of Prostate-Specific Antigen on mouse bone metastasis from prostate cancer 2009
Itraconazole as a novel Hedgehog pathway antagonist in cancer therapy 2009
Metastatic cancer cells release glutamate to disrupt bone turnover. 2009
Metronomic ALA-PDT induces apoptosis through the inhibition of LT/#946;R 2009
Metronomic ALA-PDT induces apoptosis through the inhibition of LT\#946;R 2009
Prostate cancer induced bone metastasis and related nociceptive alterations in an animal model 2009
The pathophysiology of stromal cell-derived PTHrP in giant cell tumor of bone 2009
Modelling the cost-effectiveness of first, second and third generation polychemotherapy regimens in women with early breast cancer who have differing prognoses 2009
Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizurnab (BV) or placebo (PL) in the AVADO phase III study 2009
The impact of preoperative breast magnetic resonance imaging (MRI) on surgical decision-making in young patients with breast cancer. 2009
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors 2008
Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status 2006
Downregulation of galectin-1 in androgen-independent prostate cancer cells leads to impairment of survival and reduction in invasive capacity 2006
Loss of heterozygosity analysis of parathyroid adenomas by single nucleotide polymorphism arrays 2006
Multiple post-translational modifications of E-cadherin during ER stress and apoptosis 2006
Role of IGFBP-3 in the proliferation of MDA-MB-231 breast carcinoma cells in bone metastasis 2006
Secondary sexual characteristics and body size at different ages in relation to risk of prostate cancer: Results from a case-control study 2006
Spinal astrogliosis in an animal model of cancer-induced bone pain 2006
Treatment of breast cancer cells with combination therapy. 2006
Abstract PO1-27-10: Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial. 84. 2024
Abstract PO3-11-12: A Pragmatic Randomized Trial Comparing Morning versus Evening Dosing of Endocrine Therapy for Early Breast Cancer: Final Results (REaCT-CHRONO Study). 84. 2024
Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes. 84. 2024
Abstract PO5-01-11: Breast Cancer Index and comparative analysis of late distant recurrence risk with results from the TEAM trial. 84. 2024
Abstract PS16-03: Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study – the INVINCIBLE Trial. 84. 2024
Abstract 4798: MRI screening for brain metastases (BrM) versus SYMptom-directed brain imaging for patients with triple negative (TN) or HER2+ metastatic breast cancer (MBC): An ad-hoc interim analysis of a randomized phase II pilot study. 84:4798-4798. 2024
Abstract 5112: Discovery of nuclear envelope mislocalization in MYC-driven group 3 medulloblastoma. 84:5112-5112. 2024
Abstract 5238: uPAR as a novel immunotherapeutic target in recurrent glioblastoma. 84:5238-5238. 2024
Abstract 5241: Generation of allogeneic CAR-T circumvents functional deficits in patient-derived autologous product for glioblastoma. 84:5241-5241. 2024
Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors. 84:5846-5846. 2024
Abstract 60: Functional mapping of glioblastoma recurrence reveals targetable dependencies in an axonal guidance pathway in highly invasive brain cancers. 84:60-60. 2024
Abstract IA004: Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies. 84:IA004-IA004. 2024
Repurposing Two Old Friends to Fight Cancer: Caffeine and Statins. 83:2091-2092. 2023
Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses. 83:CT202-CT202. 2023
Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36. 83:CT212-CT212. 2023
Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models. 83:lb313-lb313. 2023
Abstract 1154: Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts. 83:1154-1154. 2023
Abstract 2474: Uncovering a new therapeutic vulnerability for preventing brain metastases. 83:2474-2474. 2023
Abstract 5041: TEM-1 targeted alpha therapeutic [Ac-225]-FPI-1848 induces regression in pre-clinical sarcoma xenograft models. 83:5041-5041. 2023
Abstract 5045: NTSR1-targeted alpha therapeutic [Ac-225]-FPI-2059 induces growth inhibition in a preclinical colorectal tumor model. 83:5045-5045. 2023
Abstract 6028: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. 83:6028-6028. 2023
Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007). 83. 2023
Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. 83. 2023
Abstract P2-02-04: De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. 83. 2023
Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial. 83. 2023
Abstract P2-13-04: Inclusion of Patients with Leptomeningeal Disease in Phase III Randomized Clinical Trials of Patients with Advanced Breast Cancer, Lung Cancer, and Melanoma: A Systematic Review. 83. 2023
Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC). 83. 2023
Abstract P4-02-16: Prognostic and Predictive Capacity of Tumor Infiltrating Lymphocytes in the MA.20 regional radiotherapy trial. 83. 2023
Abstract P4-03-28: Patient Reported Symptom Burden Amongst Immigrant and Canadian Long-Term Resident Women Undergoing Breast Cancer Surgery. 83. 2023
Abstract P5-04-04: Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?. 83. 2023
Abstract P6-04-02: Ki67 Assessment Protocol: Companion Diagnostic Biomarker for LUMINA Prospective Cohort Study. 83. 2023
Abstract P6-05-12: Understanding Patient Perspectives on Window of Opportunity Clinical Trial Participation in Breast Cancer. 83. 2023
Abstract P6-10-09: Mutational landscape of breast cancer patients in ROME trial: preliminary results. 83. 2023
Abstract PD11-02: PD11-02 A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 in Early Stage Breast Cancer: the INVINCIBLE Trial. 83. 2023
Abstract 3999: HLA-G, SPAG9 and STAT3 signalling: An alliance that promotes early-stage brain metastases. 82:3999-3999. 2022
Abstract 564: Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer. 82:564-564. 2022
Abstract 60: Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma. 82:60-60. 2022
Abstract 976: Interrogating the pre-metastastic gene signature to block brain metastases. 82:976-976. 2022
Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438). 82. 2022
Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial). 82. 2022
Abstract OT1-06-01: A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer (REaCT-HOLD BMA). 82. 2022
Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605). 82. 2022
Abstract OT1-11-02: A pragmatic, randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy and its effects on tolerability and compliance (REaCT-CHRONO Study). 82. 2022
Abstract 1395: Humanized GD2 antibody for targeted radiopharmaceutical therapy of human and canine osteosarcoma. 81:1395-1395. 2021
Abstract 2528: Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415. 81:2528-2528. 2021
Abstract 2686: Preventive effects of saffron in a colitis mouse model. 81:2686-2686. 2021
Abstract 2874: Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models. 81:2874-2874. 2021
Abstract 878: Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. 81:878-878. 2021
Abstract LB130: Combination of IGF-1R targeted alpha therapy with Olaparib results in synergistic efficacy against colorectal and lung cancer xenografts. 81:LB130-LB130. 2021
Abstract LB155: Combination of IGF-1R targeted alpha therapy with checkpoint inhibitors results in synergistic efficacy in a syngeneic colorectal tumor model. 81:LB155-LB155. 2021
Abstract LB246: E-cadherin loss drives Id2-dependent dampening of cell cycle progression and predicts increased susceptibility to CDK4/6 inhibition in lobular breast cancer. 81:LB246-LB246. 2021
Abstract PO052: Uncovering the evolution of Glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers. 81:PO052-PO052. 2021
Abstract GS2-04: A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01). 81:gs2-04-gs2-04. 2021
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). 81:gs3-00-gs3-00. 2021
Abstract PD12-01: Evaluation of sleep problems and their association with febrile neutropenia, leucopenia and infections in women receiving adjuvant chemotherapy for breast cancer in the Canadian Cancer Trials Group MA.21 trial. 81:pd12-01-pd12-01. 2021
Abstract PS1-57: Mastectomy versus breast conserving surgery for the management of locally advanced breast cancer. 81:ps1-57-ps1-57. 2021
Abstract PS14-18: A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer. 81:ps14-18-ps14-18. 2021
Abstract PS7-86: Molecular determinants of racial disparity guide triple-therapy for triple negative breast cancer. 81:ps7-86-ps7-86. 2021
A Division of Labor between YAP and TAZ in Non–Small Cell Lung Cancer. 80:4145-4157. 2020
Abstract CT261: METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer. 80:CT261-CT261. 2020
Abstract PD7-08: Everolimus in first-line treatment of advanced premenopausal breast cancer: Results from MIRACLE (everoliMus trIal foR AdvanCed premenopausaL brEast cancer) study. 80:pd7-08-pd7-08. 2020
Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance. 79:5799-5811. 2019
Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies. 79:1424-1424. 2019
Abstract PD6-04: Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS). 79:pd6-04-pd6-04. 2019
Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. 78:5023-5037. 2018
Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. 78:5124-5134. 2018
Abstract 2648: Prognostic significance of thyroid hormone receptor-alpha-2 (THRα2) expression in triple-negative breast cancer: A TCGA study. 78:2648-2648. 2018
Abstract P2-10-01: Validation that a histone gene signature predicts anthracycline response in early breast cancer. 78:p2-10-01-p2-10-01. 2018
Abstract P2-10-04: Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit. 78:p2-10-04-p2-10-04. 2018
Abstract P2-11-01: Effects of radiotherapy on breast cancer outcomes among stage I, low-Recurrence risk, hormone-Sensitive breast cancer: Pooled analysis of individual data from phase III trials. 78:p2-11-01-p2-11-01. 2018
Abstract P3-08-12: Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC). 78:p3-08-12-p3-08-12. 2018
Abstract P5-07-06: Kaiso regulates miRNA-31 and miRNA-200 expression in triple negative breast cancer (TNBC) cells. 78:p5-07-06-p5-07-06. 2018
Abstract P5-19-02: Withdrawn. 78:p5-19-02-p5-19-02. 2018
Abstract 5850: Salicylate sensitizes prostate cancer (PrCa) to radiotherapy; activation of AMPK and suppression of lipogenesis. 77:5850-5850. 2017
NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of Breast Cancer. 77:2453-2463. 2017
Abstract P4-12-09: The immune response in triple negative breast cancer. 77:p4-12-09-p4-12-09. 2017
Abstract P6-12-11: A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer. 77:p6-12-11-p6-12-11. 2017
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. 76:7012-7023. 2016
Abstract 2475: Bmi1 is a therapeutic target in recurrent medulloblastoma. 76:2475-2475. 2016
Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. 76:1603-1614. 2016
Abstract P3-12-02: Lifestyle interventions combined with acupuncture-like transcutaneous electrical nerve stimulation in managing vasomotor symptoms induced by breast cancer treatment: Results of a phase 2 randomized controlled trial. 75:P3-12. 2015
miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1. 74:4145-4156. 2014
Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. 73:6734-6744. 2013
Abstract 1817: Expression of the Kaiso-binding partner Znf131 negatively correlates with cell proliferation in murine intestinal and human breast tumor tissues.. 73:1817-1817. 2013
GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. 72:5374-5385. 2012
P2-12-23: How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer.. 71:p2-12-23-p2-12-23. 2011
PD06-01: Molecular Classification with 21 Gene Assay (Oncotype DX®) Shows in 196,967 ER Positive Patients High Frequency of Low Recurrence Score [LRS] in Both Node Positive (N+) and Negative (N-) Breast Cancer (BrCa) Cohorts. Definition of Chemoresistance Based on LRS with Cost and Guideline Implications.. 71:pd06-01-pd06-01. 2011
YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth. 71:5569-5578. 2011
IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. 71:2497-2506. 2011
Maternal Embryonic Leucine Zipper Kinase Is Upregulated and Required in Mammary Tumor-Initiating Cells In vivo. 70:8863-8873. 2010
Mesenchymal Stromal Cells Expressing ErbB-2/neu Elicit Protective Antibreast Tumor Immunity In vivo, Which Is Paradoxically Suppressed by IFN-γ and Tumor Necrosis Factor-α Priming. 70:7742-7747. 2010
Metastatic Growth from Dormant Cells Induced by a Col-I–Enriched Fibrotic Environment. 70:5706-5716. 2010
Abstract 3238: Imaging sunitinib-induced vascular changes by DCE-MRI to schedule chemotherapy in renal cell carcinoma. 70:3238-3238. 2010
Abstract 43: Role of Ets-1 in the regulation of energy metabolism in cancer cells. 70:43-43. 2010
Abstract 5099: Adiponectin inhibits oxidative stress in prostate cancer cells. 70:5099-5099. 2010
Abstract 70: Mitochondrial localization of adiponectin receptor 1 (AdipoR1) induces apoptosis in cancer cells. 70:70-70. 2010
Abstract LB-147: Characterization of a Kaiso overexpressing transgenic mouse model. 70:lb-147-lb-147. 2010
Abstract LB-271: The biological role of the transcription factor Kaiso in breast tumorigenesis. 70:lb-271-lb-271. 2010
Amplification of the Prolactin Receptor Gene in Mammary Lobular Neoplasia.. 69:4151-4151. 2009
Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.. 69:13-13. 2009
Negative Regulation of β4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression. 69:5978-5986. 2009
Subcellular Localization of Cyclic AMP-Responsive Element Binding Protein-Regulated Transcription Coactivator 2 Provides a Link between Obesity and Breast Cancer in Postmenopausal Women. 69:5392-5399. 2009
Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53. 69:4818-4826. 2009
Neoadjuvant Vaccination Provides Superior Protection against Tumor Relapse following Surgery Compared with Adjuvant Vaccination. 69:3979-3985. 2009
Black Cohosh Increases Metastatic Mammary Cancer in Transgenic Mice Expressing c-erbB2. 68:8377-8383. 2008
Ultrasound Imaging of Apoptosis in Tumor Response: Novel Preclinical Monitoring of Photodynamic Therapy Effects. 68:8590-8596. 2008
Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown. 68:3707-3714. 2008
Gene Transfer of Matrix Metalloproteinase-9 Induces Tumor Regression of Breast CancerIn vivo. 68:3405-3412. 2008
Imaging Transgene Activity In vivo. 68:2878-2884. 2008
Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity. 67:10455-10465. 2007
Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44(+)alpha 2 beta 1(+) cell population is enriched in tumor-initiating cells. (vol 67, pg 6796, 2007). 67:8973-8973. 2007
Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope. 67:6459-6467. 2007
Mainstream Tobacco Smoke Causes Paternal Germ-Line DNA Mutation. 67:5103-5106. 2007
Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells. 67:2396-2401. 2007
Attenuation of the Glucocorticoid Response during Ad5IL-12 Adenovirus Vector Treatment Enhances Natural Killer Cell–Mediated Killing of MHC Class I–Negative LNCaP Prostate Tumors. 67:2290-2297. 2007
High-Grade Glioma Formation Results from Postnatal Pten Loss or Mutant Epidermal Growth Factor Receptor Expression in a Transgenic Mouse Glioma Model. 66:7429-7437. 2006
Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. 66:6040-6049. 2006
Mirk/Dyrk1b Mediates Cell Survival in Rhabdomyosarcomas. 66:5143-5150. 2006
The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. 66:4149-4158. 2006
Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors. 66:2367-2375. 2006
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes. 65:9080-9088. 2005
Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion. 64:9124-9130. 2004
Detection of an Involvement of the Human Mismatch Repair Genes hMLH1 and hMSH2 in Nucleotide Excision Repair Is Dependent on UVC Fluence to Cells. 64:3865-3870. 2004
Alternative Lengthening of Telomeres Is Characterized by High Rates of Telomeric Exchange. 64:2324-2327. 2004
Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin. 64:1509-1514. 2004
The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1 -Related Breast Cancer. 64:830-835. 2004
In vitro tests of the validity of singlet oxygen luminescence measurements as a dose metric in photodynamic therapy.. 63:7986-7994. 2003
The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer.. 63:7979-7985. 2003
Identification of a cancer stem cell in human brain tumors.. 63:5821-5828. 2003
A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer.. 63:2610-2615. 2003
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.. 63:2470-2476. 2003
Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer.. 63:2306-2311. 2003
Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.. 62:6803-6807. 2002
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.. 62:6808-6811. 2002
Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.. 62:5528-5535. 2002
In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.. 62:5148-5152. 2002
Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.. 62:1588-1591. 2002
WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.. 60:6563-6567. 2000
Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.. 60:3247-3253. 2000
Heparin/heparan sulfate interacting protein expression and functions in human breast cancer cells and normal breast epithelia.. 57:5148-5154. 1997
Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues.. 56:645-650. 1996
Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. 56:44-48. 1996
Accumulation of human promyelocytic leukemic (HL-60) cells at two energetic cell cycle checkpoints.. 55:5164-5167. 1995
Telomerase activity associated with acquisition of malignancy in human colorectal cancer.. 55:2533-2536. 1995
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.. 55:2104-2110. 1995
Expression of the prostate-specific antigen gene by a primary ovarian carcinoma.. 55:1603-1606. 1995
CHARACTERISTICS AND IN-VIVO HOMING OF LONG-TERM T-CELL LINES AND CLONES DERIVED FROM TUMOR-DRAINING LYMPH-NODES. 54:2744-2750. 1994
Cross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy.. 54:2556-2559. 1994
An upstream region of the enoyl-coenzyme A hydratase/3-hydroxyacyl-coenzyme A dehydrogenase gene directs luciferase expression in liver in response to peroxisome proliferators in transgenic mice.. 54:2303-2306. 1994
Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.. 53:5452-5457. 1993
Poly(ADP-ribose) polymerase can bind melphalan damaged DNA.. 53:5370-5373. 1993
Mitochondrial alterations in photodynamic therapy-resistant cells.. 53:4994-4999. 1993
Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents.. 53:3237-3240. 1993
COEXPRESSION OF CYTOKERATINS CHARACTERISTIC FOR MYOEPITHELIAL AND LUMINAL CELL LINEAGES IN RAT 13762NF MAMMARY ADENOCARCINOMA TUMORS AND THEIR SPONTANEOUS METASTASES. 51:5943-5950. 1991
Use of screening phase data to evaluate observer variation of sputum cytodiagnosis as an outcome measure in a chemoprevention trial.. 50:1216-1219. 1990
Role of endoscopy in the diagnosis of cancer: a consensus statement prepared by a working party of the International Union against Cancer.. 49:6822-6827. 1989
CHARACTERIZATION OF CYTOKERATINS EXPRESSED IN METASTATIC RAT MAMMARY ADENOCARCINOMA CELLS. 49:104-111. 1989
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.. 48:6404-6410. 1988
Phase I trial of lonidamine with whole body hyperthermia in advanced cancer.. 48:6587-6592. 1988
Effects of ionizing radiation and pretreatment with [D-Leu6,des-Gly10] luteinizing hormone-releasing hormone ethylamide on developing rat ovarian follicles.. 47:5005-5008. 1987
Antiproliferative effects of suramin on lymphoid cells.. 47:4694-4698. 1987
Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat.. 47:2340-2343. 1987
DEVELOPMENT OF PRIMARY AND SECONDARY IMMUNE-RESPONSES TO MOUSE MONOCLONAL-ANTIBODIES USED IN THE DIAGNOSIS AND THERAPY OF MALIGNANT NEOPLASMS. 46:6489-6493. 1986
Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.. 46:6489-6493. 1986
Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.. 46:1939-1942. 1986
A nontoxic system for 41.8 degrees C whole-body hyperthermia: results of a Phase I study using a radiant heat device.. 45:3937-3944. 1985
Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer.. 45:3347-3353. 1985
DNA amplification and tumorigenicity of the human melanoma cell line MeWo.. 45:642-647. 1985
Cell cycle kinetics of rat hepatocytes in early putative preneoplastic lesions in hepatocarcinogenesis.. 44:2913-2917. 1984
Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer.. 44:1706-1711. 1984
Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues.. 43:505-512. 1983
Reduced capacity to repair irradiated adenovirus in fibroblasts from xeroderma pigmentosum heterozygotes.. 40:3945-3949. 1980
A relative deficiency of cytochrome P-450 and aryl hydrocarbon [benzo(a)pyrene] hydroxylase in hyperplastic nodules induced by 2-acetylaminofluorene in rat liver.. 36:3888-3893. 1976
RELATIVE DEFICIENCY OF CYTOCHROME-P-450 AND ARYL-HYDROCARBON [BENZO(A)PYRENE] HYDROXYLASE IN HYPERPLASTIC NODULES INDUCED BY 2-ACETYLAMINOFLUORENE IN RAT-LIVER. 36:3888-3893. 1976
DAMAGE TO MAMMALIAN-CELL DNA BY NITROFURANS. 35:781-784. 1975
Nitrofurans as radiosensitizers of hypoxic mammalian cells.. 32:2616-2624. 1972
Metabolism and biological effects of N 6 -( 2 -isopentenyl)-adenosine on a cell line derived from circulating leukocytes of a patient with chronic myelogenous leukemia.. 32:1647-1650. 1972
Breakage of bacterial DNA by nitrofuran derivatives.. 31:2184-2188. 1971
COMPARISON OF MACROMOLECULAR BINDING OF ESTRADIOL IN HORMONE-DEPENDENT AND HORMONE-INDEPENDENT RAT MAMMARY CARCINOMA. 31:1440-&. 1971
Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate.. 30:2636-2644. 1970
The effect of-beta-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells.. 30:2627-2635. 1970
Characterization of Acquired Epipodophyllotoxin Resistance in a Chinese Hamster Ovary Cell Line: Loss of Drug-stimulated DNA Cleavage Activity \textbar Cancer Research 1986
Damage to mammalian cell DNA by nitrofurans. 1975

Cancer Research Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)